OUR EVOLUTION

Over the last 2 decades, we have grown from a single manufacturing facility focused on the Indian market to four locations producing scores of products, approvals from multiple regulators and a global reach.

  • 2001

    Glenmark Pharmaceuticals established its API business *

    *Prior to the API business being transferred to Glenmark Life Sciences pursuant to the Business Purchase Agreement.

  • 2002

     Established manufacturing plant at Kurkumbh, Maharashtra*

    *Prior to the API business being transferred to Glenmark Life Sciences pursuant to the Business Purchase Agreement.

  • 2003

    First product registered with US FDA*
    Acquired Glaxo SmithKline’s (GSK) API manufacturing plant in Ankleshwar, Gujarat *

    *Prior to the API business being transferred to Glenmark Life Sciences pursuant to the Business Purchase Agreement.

  • 2004

    Commenced manufacturing at Mohol, Maharashtra*

    *Prior to the API business being transferred to Glenmark Life Sciences pursuant to the Business Purchase Agreement.

  • 2008

    Ankleshwar plant at Gujarat inspected by US FDA*

    *Prior to the API business being transferred to Glenmark Life Sciences pursuant to the Business Purchase Agreement.

  • 2012

    Ankleshwar plant inspected by PMDA and AFSSAPS

    *Prior to the API business being transferred to Glenmark Life Sciences pursuant to the Business Purchase Agreement.

  • 2013

    Commenced manufacturing at Dahej, Gujarat*
    Ankleshwar plant inspected by COFEPRIS*

    *Prior to the API business being transferred to Glenmark Life Sciences pursuant to the Business Purchase Agreement.

  • 2015

    Dahej plant inspected by US FDA

    *Prior to the API business being transferred to Glenmark Life Sciences pursuant to the Business Purchase Agreement.

  • 2016

    Dahej plant inspected by PMDA Japan

    *Prior to the API business being transferred to Glenmark Life Sciences pursuant to the Business Purchase Agreement.

  • 2018

    Dahej plant inspected by EDQM, ANSM and US FDA*
    Mohol plant inspected by US FDA*

    *Prior to the API business being transferred to Glenmark Life Sciences pursuant to the Business Purchase Agreement.

  • 2019

    The API business was spun off into Glenmark Life Sciences
    Ankleshwar plant inspected by US FDA, Health Canada and PMDA, Japan
  • 2021

    Achieved milestone of 399 cumulative drug master files (DMFs) across multiple markets globally

Understand how we comply with the requirements of regulatory agencies around the world